Company Kinarus Therapeutics Holding AG

Equities

CURE

CH0009115129

Airlines

Market Closed - Swiss Exchange 10:38:47 2024-04-26 am EDT 5-day change 1st Jan Change
15 CHF -6.99% Intraday chart for Kinarus Therapeutics Holding AG -1.52% +737.05%

Business Summary

Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,310,175,889 822,500,536 ( 62.78 %) 8,398,873 ( 0.6410 %) 62.78 %

Shareholders

NameEquities%Valuation
CommCept AG
0.0359 %
470,000 0.0359 % 2 402 CHF
State Street Global Advisors France SA
0.001391 %
18,218 0.001391 % 93 CHF

Company contact information

Kinarus Therapeutics Holding AG

Technologiepark Basel Hochbergerstrasse 60C

4057, Basel

+

address Kinarus Therapeutics Holding AG(CURE)
  1. Stock Market
  2. Equities
  3. CURE Stock
  4. Company Kinarus Therapeutics Holding AG